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Overexpression of tumor-associated RAC1b has been recently highlighted as one of the
most promising targets for therapeutic intervention in colon, breast, lung and pancreatic can-
cer. RAC1b is a hyperactive variant of the small GTPase RAC1 and has been recently
shown to be overexpressed in a subset of papillary thyroid carcinomas associated with unfa-
vorable outcome. Using the K1 PTC derived cell line as an in vitro model, we observed that
both RAC1 and RAC1b were able to induce a significant increase on NF-kB and cyclin D1
reporter activity. A clear p65 nuclear localization was found in cells transfected with RAC1b-
WT, confirming NF-kB canonical pathway activation. Consistently, we observed a RAC1b-
mediated decrease in IκBα (NF-kB inhibitor) protein levels. Moreover, we show that RAC1b
overexpression stimulates G1/S progression and protects thyroid cells against induced apo-
ptosis, the latter through a process involving the NF-kB pathway. Present data support pre-
vious findings suggesting an important role for RAC1b in the development of follicular cell-
derived thyroid malignancies and point out NF-kB activation as one of the molecular mecha-
nisms associated with the pro-tumorigenic advantage of RAC1b overexpression in thyroid
carcinomas.
Introduction
Thyroid cancer is the most common endocrine malignancy and its incidence has rapidly
grown worldwide over the past few decades [1]. In Portugal, a significant annual increase of 2
to 9 per cent has been observed in its incidence from 1988 to 2011 [2].
The standard of care for thyroid carcinoma is surgery, regardless its histological subtype.
Most thyroid malignancies are differentiated follicular cell-derived thyroid carcinomas
(DTCs), comprising the papillary (PTC) and follicular (FTC) thyroid carcinoma subtypes
[3,4]. These forms usually respond well to the conventional therapeutic protocol, which
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consists of thyroidectomy followed by TSH suppressive therapy and, eventually, radioactive
iodine ablation therapy in selected patients accordingly to individual risk level [5]. There are,
however, advanced forms of thyroid cancer that are surgically unresectable or unresponsive to
radioiodine treatment. In those cases the therapeutic options are very limited and the 10-year
survival rate drops from 60% to only 10% [6]. Thus, understanding the molecular mechanisms
associated with tumor development and aggressiveness in order to identify novel targets for
therapeutic intervention would be clinically relevant.
Activating alterations in the canonical Ras/Raf/MEK/ERK pathway (mitogen-activated pro-
tein kinase–MAPK pathway) are considered to have key role in thyroid carcinogenesis [4,7].
Although a single oncogenic alteration in MAPK pathway might be sufficient to drive thyroid
cell tumorigenesis, additional molecular events are likely to be associated with thyroid malig-
nancy progression leading to more aggressive phenotypes and poorer clinical outcomes. Our
previous findings support that the overexpression of RAC1b, a highly activated variant of
RAC1, may be one of these modifier events: we have shown that RAC1b is overexpressed in a
subset of follicular cell-derived thyroid carcinomas compared to normal thyroid tissue and
that this overexpression is significantly associated with a poorer outcome, in both PTC and
FTC patients [8]. Nevertheless, although these findings support a role for RAC1b in thyroid
tumorigenesis, the mechanisms by which RAC1b contributes to this malignancy has not been
investigated.
RAC1b is a splice variant of the small GTPase RAC1, a member of the RAS superfamily of
small GTP-binding proteins [9]. By switching between an inactive GDP-bound form and an
active GTP-bound form [10–13] these factors regulate the activation of numerous signaling
cascades that control several cellular processes, including cell proliferation and survival
[11,13,14]. When compared to RAC1, RAC1b contains an additional domain in the vicinity of
an important regulatory region of the GTPase [11]. This addition facilitates RAC1b activation
and gives it selective downstream signaling. [15–17]. RAC1b has been described as potent
activator of only some of the RAC1 downstream pathways, particularly classical NF-kB-medi-
ated gene transcription [18,19]. Increased or constitutive NF-kB activation has been detected
in several human malignancies, consistent with many of the NF-kB regulated genes being
involved in cancer-associated processes. NF-kB activation has been also reported to play a
role in thyroid malignancies, being associated with resistance to apoptosis and maintenance
of the transformed phenotype [20–22]. The NF-kB family of transcription factors is composed
of five members [RelA(p65), RelB, c-Rel, NF-kB1 (p50 and its precursor p100), NF-kB2 (p52
and its precursor p105)] and their activity is regulated by two major pathways referred as
canonical and non-canonical. Contrary to RAC1 that activates both pathways, RAC1b selec-
tively activates the canonical pathway [18], which regulates the activity of NF-kB dimers
mostly composed of RelA(p65) and p50. These dimers are held in the cytoplasm in an inactive
form bound to the specific inhibitor IkB (inhibitor of kB). In response to stimuli, the IKK
(IkB Kinase) complex mediates the phosphorylation of IkB, inducing its degradation by the
ubiquitin-proteasome pathway. This enables free, active NF-kB dimers to translocate to the
nucleus and activate transcription of genes involved in several biological processes such as
proliferation, migration and resistance to apoptosis [23]. RAC1b was previously shown to act
as relevant player in the stimulation of cell cycle progression and cell survival through path-
ways involving NF-kB [18]. In thyroid cell systems, however, the impact of RAC1b signaling
towards the NF-kB pathway has not been investigated. With the aim of getting insights into
the molecular mechanisms associated with RAC1b overexpression and downstream signaling
in thyroid tumorigenesis, we studied the effect of RAC1b in the activity of NF-kB as well as its
impact in cellular processes associated with cancer development and progression such as cell
cycle progression and resistance to apoptotic stimuli.
RAC1b overexpression activates NF-kB in thyroid cells
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Materials and methods
Cell lines, plasmid constructs and transfections
The human PTC-derived cell line K1 was maintained in Dulbecco’s Modified Eagle Medium/
Nutrient Mixture F-12 (DMEM: F12, 1:1,Gibco, Gaithersburg, MD, USA) supplemented with
10% (v/v) fetal bovine serum (FBS) (Biochrom, Cambourne, UK), 1% (v/v) GlutaMax (Gibco),
1.25% (v/v) sodium bicarbonate (Gibco) and 0.5% (v/v) sodium pyruvate (Gibco).The cell line
Nthy-ori 3–1 (Nthy), derived from human thyroid follicular normal epithelium, was main-
tained in RPMI-1640 HEPES modified medium (Sigma, St.Louis, MO, USA), supplemented
with 10% (v/v) FBS and 1% (v/v) GlutaMax.
The plasmids used in this study [19,24] were a kind gift from Dr. Peter Jordan, from Insti-
tuto Nacional de Sau´de Dr. Ricardo Jorge: pcDNA3-HA-IκBα(A32A36), -964-CycD1-Luc vec-
tor, 3x-kB-luc vector, pRL-TK reporter (the internal control reporter constitutively expressing
Renilla luciferase), pEGFP-RAC1b-L61, pEGFP-RAC1-L61, pEGFP-RAC1b-WT, pEGF-
P-RAC1-WT. The pEGFP-C1 (BD Biosciences Clontech, Mountain View, CA, USA) and the
pcDNA3.1 (+)-empty vector (Invitrogen, Waltham, MA, USA) were used to generate mock
controls.
Transfections were carried out using Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. Cells seeded in 35mm dishes at 70–85% confluence were trans-
fected with 2μg of total plasmid DNA. The amounts used of RAC1/1b constructs were opti-
mized to achieve similar levels of protein expression (when required, the total amount of DNA
was adjusted with empty vector). For the NF-kB and cyclin D1 reporter activity assays, the
RAC1/1b constructs were co-transfected with 0.1μg of the pRL-TK (Renilla luciferase) reporter
and 1μg of NF-kB or cyclin D1 reporters. In experiments using the mutant non-degradable
“super-repressor” IκB protein (IκBaa), the RAC1/1b constructs were co-transfected with
100ng of pcDNA3-HA-IκBα (A32A36).
NF-kB and cyclin D1 reporter activity assays
For NF-kB and cyclin D1 reporter activity experiments cells were harvested 24h after transfec-
tion and lysed with passive lysis buffer 1x (Promega, Madison, WI, USA) following the manu-
facturer’s instructions. When applicable, cells were incubated with the RAC family small
GTPases inhibitor EHT 1864 (final concentration 0.1mM) for 4h before harvesting. Luciferase
activity reporter assays were performed using the Dual-Luciferase1 Reporter (DLR™) Assay
System (Promega) following the manufacturers’ instructions. Lysates were assayed in duplicate
and additional aliquots were analyzed by Western blot to assess RAC1/1b protein expression
levels.
Total protein lysates, nuclear/cytosolic extracts and western blot
Protein extracts by total cell lysis were obtained using RIPA (Radio-Immunoprecipitation
Assay) buffer. Nuclear and cytosolic extracts were prepared as described [25].Briefly, cells were
lysed in cytosol fractionating buffer [50mM HEPES (pH 7.2), 2mM EDTA, 10mM NaCl,
250mM sucrose, 2mM DTT, 0.1% (v/v) Nonidet-P40 and a protease inhibitor cocktail (Sigma)]
and the cytosolic protein extract was obtained by collecting the supernatant by centrifugation.
The nuclear protein extract was obtained by lysing the pellet in nuclei fractionating buffer
[50mM HEPES (pH 7.2), 2mM EDTA, 400mM NaCl, 20% (v/v) glycerol, 2mM DTT and prote-
ase inhibitor cocktail]. Protein samples were prepared for western blot, resolved in 12% SDS–
PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA), according to stan-
dard protocols. Primary antibodies used in this study were mouse monoclonal anti-RAC1
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(Millipore; Temecula, CA, USA) at1:2000 dilution, rabbit polyclonal anti-NF-kB p65 NLS
(Thermo Scientific, Waltham, MA, USA) at1:1000 dilution, rabbit polyclonal anti-IκBα (Santa
Cruz Biotechnology, Dallas, TX) at1:1000 dilution, mouse monoclonal anti-β-actin (Sigma) at
1:10000 dilution and rabbit polyclonal anti-Histone H2B (Millipore) at 1:1000 dilution. Detec-
tion was carried out using secondary peroxidase-conjugated anti-mouse IgG (Bio-Rad) or anti-
rabbit IgG (Bio-Rad) antibodies followed by chemiluminescence.
Confocal immunofluorescence microscopy and immunohistochemistry
For imunofluorescence analysis K1 cells were grown on 10 X 10mm glass cover slips and trans-
fected as described above. Immunofluorescence was performed as previously described [19].
NF-kB-p65detection was carried out using rabbit anti-NF-kB p65 NLS antibody (Thermo Sci-
entific) at 1:750 dilution (4˚C, overnight) followed by goat anti-rabbit secondary antibody,
Alexa Fluor1 532 (Life Technologies, Waltham, MA, USA) at 1:500 dilution. Images were
recorded with the 405-nm, 488-nm, and 532-nm laser lines of a Leica TCS-SPE confocal
microscope and processed with Adobe Photoshop software. Immunohistochemical detection
of NF-kB-p65 protein was performed on archived formalin-fixed, paraffin embedded PTC
samples. The selected PTCs have been previously assessed for RAC1b expression and BRAF
mutational status [8]. NF-kB detection was performed in 4 RAC1b-positive and 4 RAC1b-neg-
ative tumors (1 out of 4 RAC1b-positive and 1 out of 4 RAC1b-negative tumors carried BRAF
V600E mutation); the adjacent normal tissue in each tumor sample was analyzed as control.
Immunostaining was performed manually using the peroxidase-indirect-polymer method
(Dako, Code 5007 Glostrup, Denmark). 3μm thick sections were cut from paraffin-embedded
routine tissue blocks, and transferred into Superfrost plus slides. Sections were de-waxed,
rehydrated and subjected to epitope antigen retrieval (20 minutes, 94˚C) with Dako Envision
Flex Target Retrieval Solution High pH 50x (Code K8004) in a pre-treatment module PTlink
(Dako, Model PT 10130). Primary polyclonal anti-NF-kB p65 NLS antibody (Thermo Scien-
tific, 1:3000, overnight) was used. Endogenous peroxidase was inactivated with peroxidase
blocking solution (Dako, code S2023) for 15 minutes. Counterstaining was performed with
Mayer’s haematoxylin. For negative controls, primary antibodies were omitted during the
staining.
Cell cycle and cell death analysis by flow cytometry
K1 cells were transfected as described above. For cell cycle experiments, 6 hours after transfec-
tion, cells were synchronized by serum starvation (1%FBS, DMEM: F12 for 12h) and then
stimulated (10% FBS, DMEM: F12 for 6 hr), fixed and permeabilized. The fraction of cells in
each phase of cell cycle (G1, S, and G2/M) was determined by DNA content analysis using pro-
pidium iodide staining (PI—50μg/mL) followed by flow cytometry. For cell death analysis, 24
hours after transfection cells were incubated in fresh medium for two additional hours in the
absence or presence of staurosporine (Santa Cruz Biotechnology) at selected final concentra-
tions (5nM and 50nM). Stages of cell death were determined by flow cytometry, based on the
combined cell staining with PI (2μg/mL) (Sigma, USA) and Annexin V (0.75μg/mL) (BioLe-
gend, San Diego, CA; USA). Acquisition parameters were defined with the software BD Cell
Quest; cells were acquired in the flow cytometer (FACScalibur–Becton Dickinson); acquired
data was analysed using FlowJo (Tree Star Inc, USA) software.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 5 software (San Diego, USA). When-
ever appropriate, values are expressed as mean ± SD (Standard deviation). The two-tailed
RAC1b overexpression activates NF-kB in thyroid cells
PLOS ONE | DOI:10.1371/journal.pone.0172689 February 24, 2017 4 / 13
Student’s t-test or two-tailed Fisher’s exact test and the paired two-tailed Student’s t-test were
used to perform statistical analysis and evaluate statistical significance of results (accepted as
p<0.05).
Results
RAC1b stimulates canonical NF-kB reporter activation
Due to its high activity and selective signaling properties, RAC1b was shown to be a potent
inducer of the canonical NF-kB pathway in colorectal cancer cells [18]. Here, we addressed the
impact of RAC1b overexpression on NF-kB pathway, in the context of thyroid malignancies.
For that we selected the normal (Nthy) and PTC-derived (K1) cell lines, which do not express
detectable levels of RAC1b (Fig 1A), and tested the activity of a luciferase reporter regulated by
the NF-kB-consensus motif in the presence and absence of RAC1b ectopic expression (Fig
1B). Cells were transfected with the luciferase-based reporter vector and either with the RAC1
or RAC1b wild-type forms or the constitutively active mutants, RAC1- and RAC1b-L61. The
overexpression of RAC1b-WT and RAC1b-L61 in both PTC and normal cell lines induced a
significant increase on reporter activation relatively to mock-transfected, control cells. Nota-
bly, in Nthy cells, RAC1 induced a more effective reporter response than RAC1b. Conversely
in PTC-derived K1 cells RAC1b induced a considerably higher increase in reporter activity
than that produced by RAC1 (Fig 1B). In addition, treatment with the RAC1/RAC1B selective
inhibitor EHT1864, abrogated the observed effects in NF-kB reporter activity (Fig 1C), sup-
porting the role of RAC1b in the stimulation of the NF-kB pathway in both cell lines.
RAC1b downregulates IkBα and stimulates p65 (RelA) translocation to
the nucleus
To further confirm the RAC1b impact on the activation of the canonical NF-kB pathway in K1
cells, we study the influence of RAC1b on total IκBα protein expression (a negative regulator
in the canonical NF-kB pathway) that is inversely correlated with the activation of NF-kB tran-
scription factor. We observed a decrease of total IκBα levels upon ectopic overexpression of
RAC1b (either WT or Q61L) (Fig 2A). The impact of RAC1b overexpression on the activation
of the transcription factor NF-kB was further addressed by accessing its effect on the nuclear
translocation of p65. Firstly, the effect of RAC1b on the subcellular localization of p65 was
accessed by immunofluorescence using an antibody that binds the uncovered NLS region of
p65 (i.e. the active p65 dimers). K1 cells were transfected with GFP-RAC1-WT, GFP-RAC1b-
WT or control GFP-empty vector. As shown in Fig 2B, cells transfected with RAC1b-WT
revealed a clear nuclear localization of p65, compared to non-transfected or to GFP transfected
cells. In contrast, RAC1-WT had little effect on the accumulation of p65 in the nucleus. This
observation was further confirmed by subcellular fractionation experiments where an increase
on chromatin-associated p65 was clearly detected in the nuclear fraction upon the expression
of RAC1b, but not of RAC1 (Fig 2C). All these observations are consistent with the effects
observed in the activity of the NF-kB reporter.
To assess the biological significance of these findings we investigated whether p65 nuclear
localization could distinguish RAC1b-positive from RAC1b-negative PTC tumor samples.
Using immunohistochemistry we tested paraffin-embedded tissue specimens representative
of both tumor types and evaluate differences in subcellular localization of the p65-NLS pro-
tein. As illustrated in Fig 3, the nuclear localization of NF-kB/p65 was found to be prevalent
in RAC1b-overexpressing tumors when compared to those that are negative for RAC1b
expression.
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RAC1b protects PTC-derived cells against apoptosis via the NF-kB
pathway
Since one of the most relevant cancer-related effects of NF-kB stimulation is anti-apoptotic
response, the impact of RAC1b overexpression in this process was further addressed.
Fig 1. Luciferase activity of NF-kB regulated reporter in transfected K1 and Nthy cells. (A) Western blot
documenting endogenous RAC1/1b expression in K1 and Nthy cell lines; RAC1b- overexpressing and non-
overexpressing PTC samples were included as controls (PTC a, PTC b and PTC c). (B) Luciferase reporter
activity driven by the NF-κB consensus motif upon expression of transfected GFP-RAC1/1b in K1 and Nthy
cells. Western Blot documenting expression levels of transfected GFP-RAC1/1b in both cell lines. Beta-actin
was used as a loading control. (B) Activity of NF-kB regulated reporter in K1 cells transfected with RAC1/1b
variants upon treatment with EHT 1864. Western Blot documenting the expression of transfected RAC1/1b
variants. RAC1/1b expression was assessed using anti-RAC1 primary antibody which detects both RAC1 and
RAC1b variants Data are mean ± error bars (SD) of at least three independent experiments. Comparison of
RAC1/1b effects with mock control was performed using a two-tailed Student’s t-test. A paired two-tailed
Student’s t-test was used to evaluate the effect of EHT 1864 comparing treated with non-treated cells; p-
values: *p0.05 **p0.01 ***p0.001.
doi:10.1371/journal.pone.0172689.g001
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K1 cells were subjected to different concentrations of staurosporine and the proportion of
apoptotic cells evaluated by flow cytometry in the presence and absence of RAC1b expression
(Fig 4). As expected, the proportion of apoptotic mock-transfected cells increased with increas-
ing concentrations of staurosporine. In contrast, RAC1b- expressing cells were clearly resistant
Fig 2. Effect of RAC1b overexpression on the subcellular location of NF-kB-p65 subunit. K1 cells were
transfected with pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or pEGFP-empty vector (Mock). (A) Western blot
documenting IκBα levels upon GFP-RAC1b transfection in K1 cells. Protein levels were determined by
densitometry using ImageJ software on blots from three independent experiments and results are expressed
as mean values; two-tailed Student’s t-test was used to compare the effect of RAC1b expression with Mock
control; p-values: *p0.05 **p0.01 ***p0.001. (B) Immunofluorescence confocal microscopy using anti-
NF-kB p65-NLS antibody; nuclei were counterstained with DAPI. The overlay image of the DAPI, GFP and
Red channels is shown. (C) Western Blot accessing NF-kB-p65-NLS in nuclear and cytoplasmic cell fractions.
Histone H2B and β-Actin were used as nuclear and cytoplasmic loading controls, respectively.
doi:10.1371/journal.pone.0172689.g002
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to apoptotic stimuli, even when treated with the highest concentration of staurosporine. This
resistance was abated by co-expression of the non-degradable IκBαA32A36 super-repressor
mutant (IkBAA), indicating that the observed RAC1b-induced apoptosis resistance operates
through the canonical pathway of NF-kb activation.
RAC1b stimulates cyclin D1 reporter and cell cycle progression by a
mechanism that is independent of NF-kB
Since a role for RAC1b signaling in cell cycle progression that involves NF-kB activation and
cyclin D1 expression has been previously reported [18], we tested whether this effect was rele-
vant in a PTC biological system. We started to test the ability of RAC1/1b to stimulate the
activity of a Cyclin D1 reporter in K1 cells. Both the WT and L61 forms of either RAC1 or
RAC1b increased luciferase activity over control cells (Fig 5A). Also, an increase on protein
levels of Cyclin D1 was observed upon expression of RAC1b variants compared to mock con-
trol (Fig 5B). The Cyclin D1 reporter induced activity, however, was similar for the different
RAC1/1b forms and modest in magnitude (1.3-fold) as compared to that obtained for the NF-
kB reporter (2 to 3-fold). This led us to address whether the effect of RAC1b on the cyclin D1
Fig 3. Immunohistochemical analysis of NF-kB in RAC1b-positive and RAC1b-negative PTC
samples. NF-kB p65-NLS immunostaining patterns in representative normal thyroid and in RAC1b-
overexpressing or RAC1b-negative tumor samples A positive nuclear staining was found to be prevalent in
RAC1b-overexpressing tumors. Images were acquired with a Leica DMD 108 microscope; magnification: A)
5X; B) 20X; C) 40X.
doi:10.1371/journal.pone.0172689.g003
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reporter was sufficient to impact cell cycle progression. Notably, we observed an increase in
cell populations in S/G2 upon ectopic expression of either RAC1b-wt or–L61 (Fig 5C and 5D).
However, while these effects were clearly reverted by co-treatment with the RAC1b inhibitor
EHT 1864 (Fig 5D and 5E) neither was affected by co-expression of the IkBAA super-repressor
(Fig 5C). Altogether, these results indicate that the mechanism of cell cycle progression
induced by RAC1b works independently of NF-kB activation. Lastly, we aimed to ascertain
whether the ability of RAC1b to induce cyclin D1 is still present in a different thyroid cell sys-
tem, acting independently of the constitutive activation of BRAF V600E/MAPK pathway. To
address this point, the effect of RAC1b in cyclin D1 reporter was additionally accessed in Nthy
cells, which do not harbor BRAF V600E or other MAPK activating mutations. In this cell sys-
tem, RAC1b was still able to induce cyclin D1 reporter activity to levels higher than that of
mock control (Fig 5F), indicating that RAC1b-induced cyclin D1-associated cell cycle effects
may work on thyroid cell systems even in the absence of the BRAF V600E/MAPK- activational
effects.
Discussion
The standard of care for differentiated follicular cell- derived thyroid carcinomas includes thy-
roidectomy, TSH suppressive therapy and eventually radioactive iodine treatment for selected
patients accordingly to individual risk. Despite being usually associated with a good prognosis
the rate of recurrence is high and a subset of patients presents radioiodine refractory and non-
responsive neoplasias. So, the search for new therapeutic alternatives, as well as new diagnos-
tic/prognostic markers is clinically relevant.
We have previously shown that RAC1b is overexpressed in a subset of thyroid follicular
cell-derived carcinomas (of either PTC or FTC subtypes) associated with poorer outcomes.
These findings suggest a role for RAC1b in the modulation of thyroid malignant progression.
However, the mechanism by which RAC1b signaling impacts on thyroid tumorigenesis
remained elusive. Similarly, several lines of evidence have implicated NF-kB in thyroid cancer
progression but the mechanism leading to NF-KB activation in thyroid tumorigenesis is still
poorly defined [20,26]. Here, we hypothesized that RAC1b might contribute for this process
Fig 4. Effect of RAC1b overexpression on apoptosis. (A) Apoptotic cell death assessed by flow cytometry
in K1 cells transfected with RAC1/1b variants upon apoptosis induction with increasing amounts of the
proapoptotic agent, staurosporine. Levels of apoptosis were also evaluated upon co-expression of the non-
degradable super-repressor IκBαA32A36 (IκBaa). Data are means ± error bars (SD) of at least three individual
experiments. Comparisons were made using a two-tailed Student’s t-test. *p0.05 **p0.01 ***p0.001.
doi:10.1371/journal.pone.0172689.g004
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since RAC1b has been also shown to be a potent activator of the canonical NF-κB regulatory
pathway in colorectal cancer. Therefore, in this study we addressed whether RAC1b retains the
ability to stimulate NF-kB activation in thyroid biological systems and if this activation would
be relevant for thyroid tumorigenesis.
Using the human PTC- derived K1 cell line as in vitro model, we observed that both RAC1
and RAC1b were able to induce a significant increase on NF-kB reporter activity. Also, a clear
Fig 5. Effect of RAC1b overexpression on Cyclin D1 reporter and cell cycle progression. (A) Effect of
RAC1/1b variants on luciferase activity derived from cyclin D1 regulated reporter in K1 cells. (B) Western blot
documenting the protein levels of Cyclin D1 upon expression of RAC1/1b variants. (C) Flow cytofluorometric
analysis of cell cycle assessed in the presence/absence of IκBaa. (D) Flow cytofluorometric analysis of
cell cycle in the presence/absence of EHT 1864. The percentages of cells in each phase of cell cycle is
represented. (E) Effect of RAC1b on luciferase activity derived from cyclin D1 regulated reporter in the
presence/absence of the specific RAC inhibitor EHT 1864. (F) Effect of RAC1/1b variants on luciferase
activity derived from cyclin D1 regulated reporter in Nthy cells. Data are means ± error bars (SD) of at least
three individual experiments. Comparisons with the Mock control in each condition were performed using a
two-tailed Student’s t-test; p-values: *p0.05 **p0.01 ***p0.001.
doi:10.1371/journal.pone.0172689.g005
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p65 nuclear localization was found in cells transfected with RAC1b-WT, confirming the acti-
vation of the NF-kB canonical pathway. Importantly, we confirmed that these in vitro observa-
tions were present in patient-derived samples, since nuclear-localized NF-kB was prevalent in
RAC1b-overexpressing PTCs when compared to RAC1b- negative tumors. These findings
prompted us to further assess the cellular consequences of RAC1b-mediated NF-kB activation
in a thyroid biological system. Consistent with previous observations in other cell types, we
observed that RAC1b expression significantly increased the resistance of PTC cells to apoptotic
stimuli via stimulation of the NF-kB pathway [18,19]. Surprisingly, however, RAC1b ability to
stimulate Cyclin D1and G1/S progression in PTC is independent of NF-kB activation, which is
in contrast to previous observations in other carcinomas, namely colorectal carcinomas [18].
This suggests that in the thyroid biological context other RAC1b-stimulated pathways contrib-
ute to cell proliferation. Notably, we found additional indications of different RAC1b signaling
contexts between colorectal and thyroid malignancies. Here we showed that in the PTC cells
RAC1b induces NF-kB activation to substantially greater levels than RAC1, whereas in colo-
rectal cancer cells RAC1 appears to be a more effective NF-kB activator than RAC1b [19].
Moreover, our results in thyroid indicate that the biological context of RAC1b signaling may
also differ between normal and cancer tissues. In fact, in cells derived from normal follicular
epithelium, RAC1 prevails over RAC1b in what concerns their signaling to the NF-kB path-
way. This suggests that RAC1b overexpression acquires pro-tumorigenic relevance only in the
context of an already altered cellular background. When we tested two other available PTC-
derived cell lines, BCPAP and TPC1 (neither of which express RAC1b; S1A Fig), we found the
NF-kB pathway to be so highly stimulated that even in basal conditions (mock control trans-
fections) the luciferase reporter levels exceeded those of K1 cells overexpressing RAC1b-L61
(S1B Fig). Moreover, no significant reporter variations were observed in these cell lines upon
overexpression of either RAC1 or RAC1b constitutively active mutants. This is consistent with
the cellular background influencing NF-kB activity and with the hypothesis that the right con-
text is required for RAC1b overexpression to become relevant in thyroid tumorigenesis.
Although both K1 and BCPAP cells harbor the BRAF V600E mutation they present different
NF-kB activation profiles. This suggests that BRAF activating mutations alone do not rule NF-
kB activational status. K1 also harbors a PIK3CA E545K mutation which could be generating
the right background to promote signaling through RAC1b, since this variant is much more
easily activated that RAC1 [16]. However, TPC1 cells harbor a RET/PTC1 rearrangement
which signals both trough BRAF and PI3K, and presented a NF-kB activation profile much
more similar to BCPAP than to K1. This indicates that despite the reported synergy between
RAC1b and BRAF V660E in colorectal tumors [27], the altered molecular background that
promotes a RAC1b-induced NF-kB-mediated pro-oncogenic response in thyroid cancer
remains elusive and probably goes beyond bone-fide genetic alterations in genes such as
BRAF, PI3K or RET. Nonetheless our data indicate that during the malignant progression of
some thyroid tumors the arising of RAC1b overexpression may suffice to offer tumor cells an
additional survival advantage through NF-kB stimulation. This, in turn, can lead to more
aggressive phenotypes and poorer clinical outcomes, as reported in both PTCs and FTCs
[8,28].
In conclusion, taken together, our findings suggest an important role of RAC1b overexpres-
sion signaling through NF-kB in PTC tumorigenesis through apoptosis resistance. Moreover,
our results indicate that RAC1b may also impact PTC cell proliferation through yet uncharac-
terized pathways. Together with the identified differences in RAC1b signaling between normal
and neoplastic thyroid cells, our data open new research avenues for the study of small GTPase
signaling in the context of thyroid cancer.
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Supporting information
S1 Fig. Comparison of NF-κB regulated reporter activity in N-Thy, K1, BCPAP and TPC1
thyroid cell lines. (A) Western blot documenting endogenous RAC1b expression in K1, Nthy,
BCPAC and TPC1 cell lines; a RAC1b- overexpressing PTC sample was included as control
(PTC RAC1b+). (B) Luciferase reporter activity driven by the NF-κB consensus motif in basal
(mock control transfection) conditions and upon expression of either GFP-RAC1b-L61 or
GFP-RAC1-L61 in K1, Nthy, BCPAP and TPC1 cell lines. Data are mean ± error bars (SD) of
at least three independent experiments.
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